KDIGO guidelines for the management of blood pressure in chronic kidney disease: A sprint to the curve

Published:September 29, 2021DOI:


      • New KDIGO Guidelines recommend straight blood pressure control in renal disease.
      • Available evidence shows a J Curve effect of blood pressure control on morbimortality in kidney disease patients.
      • Intensive blood pressure control should be avoided in most chronic kidney disease patients.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to European Journal of Internal Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


      1. Kidney disease: improving global outcomes (KDIGO) Blood Pressure Work Group. KDIGO 2021 clinical practice guideline for the management of blood pressure in chronic kidney disease.
        Kidney Int. 2021; 99: S1-S87
        • Whelton PK
        • Carey RM
        • Aronow WS
        • Casey Jr, DE
        • Collins KJ
        • Dennison Himmelfarb C
        • et al.
        ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines.
        J Am Coll Cardiol. 2017; 71 (2018 May 15): e127-e248
        • Wright Jr, JT
        • Williamson JD
        • Whelton PK
        • Snyder JK
        • Sink KM
        • Rocco MV
        • SPRINT Research Group
        A randomized trial of intensive versus standard blood-pressure control.
        N Engl J Med. 2015; 373: 2103-2116
      2. Williams B, Mancia G, Spiering W, et al.; Authors/Task Force Members. 2018 ESC/ESH Guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Cardiology and the European Society of Hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Cardiology and the European Society of Hypertension. J Hypertens. 2018;36(10):1953-2041.

        • Jafar TH
        • Stark PC
        • Schmid CH
        • Landa M
        • Maschio G
        • de Jong PE
        • AIPRD Study Group
        Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensinconverting enzyme inhibition: a patient-level meta-analysis.
        Ann Intern Med. 2003; 139: 244-252
        • Upadhyay A
        • Earley A
        • Haynes SM
        • Uhlig K.
        Systematic review: blood pressure target in chronic kidney disease and proteinuria as an effect modifier.
        Ann Intern Med. 2011; 154: 541-548
        • Sim JJ
        • Shi J
        • Kovesdy CP
        • Kalantar-Zadeh K
        • Jacobsen SJ.
        Impact of achieved blood pressures on mortality risk and end-stage renal disease among a large, diverse hypertension population.
        J Am Coll Cardiol. 2014; 64: 588-597
        • Stewart IM.
        Relation of reduction in pressure to first myocardial infarction in patients receiving treatment for severe hypertension.
        Lancet. 1979; 1: 861-865
        • Panjrath GS
        • Chaudhari S
        • Messerli FH.
        The j-point phenomenon in aggressive therapy of hypertension: new insights.
        Curr Atheroscler Rep. 2012; 14: 124-129
        • Böhm M
        • Schumacher H
        • Teo KK
        • Lonn EM
        • Mahfoud F
        • Mann JFE
        • et al.
        Cardiovascular outcomes and achieved blood pressure in patients with and without diabetes at high cardiovascular risk.
        Eur Heart J. 2019; 40: 2032-2043
        • Viazzi F
        • Leoncini G
        • Grassi G
        • Pontremoli R.
        Antihypertensive treatment and renal protection: is there a J-curve relationship?.
        J Clin Hypertens (Greenwich). 2018; 20: 1560-1574
        • Robles NR
        • Hernandez-Gallego R
        • Fici F
        • Grassi G.
        Does a blood pressure J curve exist for patients with chronic kidney disease?.
        J Clin Hypertens (Greenwich). 2017; 19: 764-770
        • Cheung AK
        • Rahman M
        • Reboussin DM
        • Craven TE
        • Greene T
        • Kimmel PL
        • et al.
        SPRINT Research Group. Effects of intensive BP control in CKD.
        J Am Soc Nephrol. 2017; 28: 2812-2823
        • Agabiti Rosei E.
        Target blood pressure for treatment: should current recommendations be changed?.
        Hypertension. 2016; 68 (Aug): 263-265
        • Wang TD
        • et al.
        Increased all-cause mortality with intensive blood-pressure control in patients with a baseline systolic blood pressure of >160 mmHg and a Lower Framingham risk score: a cautionary note from SPRINT.
        in: European Society of Cardiology 2017 Congress. 2017 (August 28Barcelona, Spain. Abstract 3828)
        • Sun X
        • Guo Y
        • Nie Z
        • Cheng J
        • Zhou H
        • Zhong X
        • et al.
        Influence of baseline systolic blood pressure on the relationship between intensive blood pressure control and cardiovascular outcomes in the Systolic Blood Pressure Intervention Trial (SPRINT).
        Clin Res Cardiol. 2019; 108: 273-281
        • Li J
        • Somers VK
        • Gao X
        • Chen Z
        • Ju J
        • Lin Q
        • et al.
        Evaluation of optimal diastolic blood pressure range among adults with treated systolic blood pressure less than 130 mm Hg.
        JAMA Netw Open. 2021; 4 (Feb 1PMID: 33595663; PMCID: PMC7890449)e2037554